Clinical trials · California
Non-Muscle Invasive Bladder Urothelial Carcinoma clinical trials in California
We’re tracking 14 recruiting non-muscle invasive bladder urothelial carcinoma studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Bakersfield, CaliforniaAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Bakersfield, CaliforniaAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide study for early bladder cancer in men
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Los Angeles, CaliforniaAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06995677RecruitingPhase 2
TYRA-300 pill for low-grade bladder cancer with FGFR3 change
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
Murrieta, CaliforniaAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Los Alamitos, CaliforniaAges 18 years+ - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Irvine, CaliforniaAges 18 years+ - NCT07480356RecruitingPhase 3
Testing a new bladder cancer treatment (TARA-002) vs standard chemo
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Bakersfield, CaliforniaAges 18 years+ - NCT07673016Recruiting
Collecting urine to test a new bladder cancer detection method
This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.
San Jose, CaliforniaAges 18 years+ - NCT06668493RecruitingPhase 1/Phase 2
A virus-based treatment for low-grade upper tract bladder cancer
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
Santa Monica, CaliforniaAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Auburn, CaliforniaAges 18 years+
Non-Muscle Invasive Bladder Urothelial Carcinoma trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting non-muscle invasive bladder urothelial carcinoma studies listed above.
- University of California, Irvine Medical Center / UC Irvine Health · 4 studies
- Michael G Oefelein Clinical Trials · 3 studies
- USC / Norris Comprehensive Cancer Center · 3 studies
- American Institute of Research · 2 studies
- Cedars-Sinai Medical Center · 2 studies
- City of Hope Comprehensive Cancer Center · 2 studies
- Genesis Research, LLC · 2 studies
- Los Angeles General Medical Center · 2 studies
What taking part in a non-muscle invasive bladder urothelial carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Non-Muscle Invasive Bladder Urothelial Carcinoma trials in other states
Common questions
- Are there non-muscle invasive bladder urothelial carcinoma clinical trials in California?
- Yes. We're currently tracking 14 recruiting non-muscle invasive bladder urothelial carcinoma studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non-muscle invasive bladder urothelial carcinoma study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non-muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non-muscle invasive bladder urothelial carcinoma studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.